Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin in metastatic urothelial cancer
NCT02013765Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2001
- Primary completion
- Jan 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in urothelial carcinoma (UC), sponsored by Roche. Started Jan 2001; status: terminated.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02013765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013765.